The role of chemotherapy in the treatment of patients with brain metastases from solid tumors (Q37586262)

21 August 2017

1 reference

title

The role of chemotherapy in the treatment of patients with brain metastases from solid tumors (English)

1 reference

21 August 2017

0 references

1 reference

Tobias Walbert

1

1 reference

21 August 2017

Mark R Gilbert

series ordinal

2

1 reference

21 August 2017

publication date

25 August 2009

1 reference

International Journal of Clinical Oncology

21 August 2017

published in

1 reference

21 August 2017

volume

14

1 reference

21 August 2017

issue

4

1 reference

21 August 2017

page(s)

299-306

1 reference

Identification of prognostic factors in patients with brain metastases: a review of 1292 patients

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10147-009-0916-1

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-009-0916-1

Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-009-0916-1

The response of cerebral metastases in small cell lung cancer to systemic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-009-0916-1

Brain metastases: treatment options to improve outcomes

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

The natural history of breast cancer patients with brain metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Distribution of brain metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Long-term survival with metastatic cancer to the brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Chemotherapy induces regression of brain metastases in breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Brain metastases: still an 'orphan' disease?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Brain metastases: the HER2 paradigm

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Primary chemotherapy of brain metastasis in small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

https://pubmed.ncbi.nlm.nih.gov/19705239

1 reference

12 December 2020

A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Brain metastases: epidemiology and pathophysiology

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

A phase II trial of temozolomide for patients with recurrent or progressive brain metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Brain metastases. Histology, multiplicity, surgery, and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

CNS metastases in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Response of brain metastases from breast cancer to systemic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Intracerebral metastases in solid-tumor patients: Natural history and results of treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

The role of topotecan in the treatment of brain metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier

1 reference

https://pubmed.ncbi.nlm.nih.gov/19705239

12 December 2020

10.1007/S10147-009-0916-1

Identifiers

DOI

1 reference

21 August 2017

1 reference